You may recall that Turing Pharmaceuticals/Martin Shkreli (you know, the guy whose name you can't remember partly because he has terrible social skills, partly because of the red haze of rage associated with reading any article about what he did, partly because you've never heard that name before) raised the price on a generic that they were the sole manufacturer of.
Well, there are a lot of ways to describe what happened to him next, but it wasn't effective regulation. Because I used to work for the guy most associated with this phrase, I like "Your Margin is My Opportunity". But I'll take Commodity Hell, Low Barriers to Entry, Invisible Hand or Supply and Demand as well. Same old, same old.
Even better, "Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company based in San Diego, announced today that it has made an alternative to Daraprim that costs about a buck a pill—or $99 for a 100-pill supply." has produced an improved alternative -- combining the drug in question with another one to reduce its primary negative side effect.